Anthropic says Claude has been used in real drug programs at 6 companies
Anthropic said that over the past few months, its scientists have established deep research partnerships with 6 organizations developing new medicines, while also launching its own drug discovery efforts. Claude's work went beyond proposing molecular ideas: it generated about 35,000 antibody designs in roughly one month, coordinated 11 external laboratories for a one-person biotech company, and identified 7 production issues that human reviewers had missed. Most of this work is still at the preclinical stage, and one drug in Anthropic's own program could enter human trials as early as the end of 2028.
Why read this
AI score 65
Anthropic disclosed Claude's specific outputs in real drug programs at 6 pharmaceutical companies, which offers a window into how AI is actually dividing up work across the drug R&D chain.
Topics
View original postOver the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own. In doing so, we’ve learned much more about how Claude can support the many stages of drug development. In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences. https://t.co/EVbxkdDTgJ
View original
Over the past few months, Anthropic scientists have engaged in deep research partnerships with six organizations developing new medicines. We've also begun drug discovery efforts of our own. In doing so, we’ve learned much more about how Claude can support the many stages of drug development. In this blog post, we share some early results from these efforts, and describe how this work fits in with our wider ambitions in the life sciences. https://t.co/EVbxkdDTgJ
Body
> Anthropic now uses Claude inside real drug programs at 6 companies and runs its own, including muscular dystrophy work that could reach human trials as soon as late 2028.
> Claude handled far more than molecule ideas: it generated roughly 35K antibody designs in about a month, coordinated 11 outside labs for a one-person biotech, and caught 7 manufacturing issues human reviewers missed.
> The work remains mostly preclinical, though Anthropic’s in-house programs could put a drug into human trials as soon as late 2028.